MHC class II auto-antigen presentation is unconventional

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Sadegh Nasseri, Scheherazade ^a   Kim, AeRyon ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auto antigens; Cathepsin sensitivity; Cell free antigen processing system; Extracellular processing; HLA DR antigens; Immunodominance; Paralyzed DC

Indexed keywords

AUTOANTIGEN; CATHEPSIN; COLLAGEN TYPE 2; EPITOPE; GELATINASE B; GLIADIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; HELPER CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; SHORT SURVEY; T LYMPHOCYTE;

EID: 84938502645     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00372     Document Type: Short Survey

References (50)

1. Kim A, Sadegh-Nasseri S. Determinants of immunodominance for CD4 T cells. Curr Opin Immunol (2015) 34:9-15. doi: 10.1016/j.coi.2014.12.005
2. Riese RJ, Chapman HA. Cathepsins and compartmentalization in antigen presentation. Curr Opin Immunol (2000) 12(1):107-13. doi:10.1016/S0952-7915(99)00058-8
3. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature (1994) 368(6471):551-4. doi:10.1038/368551a0
4. Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, Khoruzhenko S, et al. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol (2007) 8(1):92-100. doi:10.1038/ni1414
5. Chou CL, Mirshahidi S, Su KW, Kim A, Narayan K, Khoruzhenko S, et al. Short peptide sequences mimic HLA-DM functions. Mol Immunol (2008) 45(7):1935-43. doi:10.1016/j.molimm.2007.10.033
6. West LC, Cresswell P. Expanding roles for GILT in immunity. Curr Opin Immunol (2013) 25(1):103-8. doi:10.1016/j.coi.2012.11.006
7. Nguyen HN, Steede NK, Robinson JE, Landry SJ. Conformational instability governed by disulfide bonds partitions the dominant from subdominant helper T-cell responses specific for HIV-1 envelope glycoprotein gp120. Vaccine (2015) 33(25):2887-96. doi:10.1016/j.vaccine.2015.04.082
8. Poluektov YO, Kim A, Hartman IZ, Sadegh-Nasseri S. HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation. PLoS One (2013) 8(8):e71228. doi:10.1371/journal.pone.0071228
9. Poluektov YO, Kim A, Sadegh-Nasseri S. HLA-DO and its role in MHC class II antigen presentation. Front Immunol (2013) 4:260. doi:10.3389/fimmu.2013.00260
10. Denzin LK, Cresswell P. Sibling rivalry: competition between MHC class II family members inhibits immunity. Nat Struct Mol Biol (2013) 20(1):7-10. doi:10.1038/nsmb.2484
11. Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, et al. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nat Med (2010) 16:1333-40. doi:10.1038/nm.2248
12. van den Hoorn T, Paul P, Jongsma ML, Neefjes J. Routes to manipulate MHC class II antigen presentation. Curr Opin Immunol (2011) 23(1):88-95. doi:10.1016/j.coi.2010.11.002
13. Yin L, Calvo-Calle JM, Dominguez-Amorocho O, Stern LJ. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives. J Immunol (2012) 189(8):3983-94. doi:10.4049/jimmunol.1200626
14. McCurley N, Mellman I. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLoS One (2010) 5(8):e11949. doi:10.1371/journal.pone.0011949
15. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 307(5715):1630-4. doi:10.1126/science.1108003
16. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science (2003) 299(5611):1400-3. doi:10.1126/science.1080106
17. Manoury B. Proteases: essential actors in processing antigens and intracellular toll-like receptors. Front Immunol (2013) 4:299. doi:10.3389/fimmu.2013.00299
18. Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev (2005) 207:229-41. doi:10.1111/j.0105-2896.2005.00310.x
19. Chapman HA. Endosomal proteases in antigen presentation. Curr Opin Immunol (2006) 18(1):78-84. doi:10.1016/j.coi.2005.11.011
20. Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: who's in charge?. Immunity (2000) 12(3):233-9. doi:10.1016/S1074-7613(00)80176-4
21. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol (2003) 3(6):472-82. doi:10.1038/nri1110
22. Pluger EB, Boes M, Alfonso C, Schroter CJ, Kalbacher H, Ploegh HL, et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol (2002) 32(2):467-76. doi:10.1002/1521-4141(200202)32:2<467::AID-IMMU467>3.0.CO;2-Y
23. Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity (1996) 4(4):357-66. doi:10.1016/S1074-7613(00)80249-6
24. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity (1999) 10(2):207-17. doi:10.1016/S1074-7613(00)80021-7
25. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science (1998) 280(5362):450-3. doi:10.1126/science.280.5362.450
26. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol (2002) 3(2):169-74. doi:10.1038/ni754
27. Watts C, Moss CX, Mazzeo D, West MA, Matthews SP, Li DN, et al. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann N Y Acad Sci (2003) 987:9-14. doi:10.1111/j.1749-6632.2003.tb06028.x
28. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A (1998) 95(8):4516-21. doi:10.1073/pnas.95.8.4516
29. Kim A, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, et al. Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nat Commun (2014) 5:5369. doi:10.1038/ncomms6369
30. Burster T, Reich M, Zaidi N, Voelter W, Boehm BO, Kalbacher H. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells. Biochem Biophys Res Commun (2008) 377(4):1299-303. doi:10.1016/j.bbrc.2008.10.162
31. Burster T, Macmillan H, Hou T, Boehm BO, Mellins ED. Cathepsin G: roles in antigen presentation and beyond. Mol Immunol (2010) 47(4):658-65. doi:10.1016/j.molimm.2009.10.003
32. Mohan JF, Petzold SJ, Unanue ER. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med (2011) 208(12):2375-83. doi:10.1084/jem.20111502
33. Fonovic M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta (2014) 1840(8):2560-70. doi:10.1016/j.bbagen.2014.03.017
34. Pislar A, Kos J. Cysteine cathepsins in neurological disorders. Mol Neurobiol (2014) 49(2):1017-30. doi:10.1007/s12035-013-8576-6
35. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 37(6): 375-536. doi:10.1080/10409230290771546
36. Flynn JC, McCormick DJ, Brusic V, Wan Q, Panos JC, Giraldo AA, et al. Pathogenic human thyroglobulin peptides in HLA-DR3 transgenic mouse model of autoimmune thyroiditis. Cell Immunol (2004) 229(2):79-85. doi:10.1016/j.cellimm.2004.07.002
37. Jordans S, Jenko-Kokalj S, Kuhl NM, Tedelind S, Sendt W, Bromme D, et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem (2009) 10:23. doi:10.1186/1471-2091-10-23
38. Mattapallil MJ, Silver PB, Mattapallil JJ, Horai R, Karabekian Z, McDowell JH, et al. Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol (2011) 187(4):1977-85. doi:10.4049/jimmunol.1101247
39. Beck H, Schwarz G, Schroter CJ, Deeg M, Baier D, Stevanovic S, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol (2001) 31(12):3726-36. doi:10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O
40. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural basis for gluten intolerance in celiac sprue. Science (2002) 297(5590):2275-9. doi:10.1126/science.1074129
41. Sollid LM, Pos W, Wucherpfennig KW. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr Opin Immunol (2014) 31C:24-30. doi:10.1016/j.coi.2014.08.005
42. Villadangos J. Mechanisms of induction of paralysed dendritic cells with poor antigen presentation function following systemic inflammatory response syndrome. J Immunol (2015) 194(1 Suppl):113.4.
43. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med (1998) 188(8):1511-20. doi:10.1084/jem.188.8.1511
44. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 24(17):2968-79. doi:10.1038/sj.emboj.7600771
45. Nicholson MJ, Moradi B, Seth NP, Xing X, Cuny GD, Stein RL, et al. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol (2006) 176(7):4208-20. doi:10.4049/jimmunol.176.7.4208
46. Mohan JF, Unanue ER. A novel pathway of presentation by class II-MHC molecules involving peptides or denatured proteins important in autoimmunity. Mol Immunol (2013) 55(2):166-8. doi:10.1016/j.molimm.2012.10.024
47. Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson HW, et al. Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A (2014) 111(7):2656-61. doi:10.1073/pnas.1323436111
48. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A (2010) 107(24):10978-83. doi:10.1073/pnas.1006545107
49. Mohan JF, Calderon B, Anderson MS, Unanue ER. Pathogenic CD4(+) T cells recognizing an unstable peptide of insulin are directly recruited into islets bypassing local lymph nodes. J Exp Med (2013) 210(11):2403-14. doi:10.1084/jem.20130582
50. Ferris ST, Carrero JA, Mohan JF, Calderon B, Murphy KM, Unanue ER. A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes. Immunity (2014) 41(4):657-69. doi:10.1016/j.immuni.2014.09.012